Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
Go back to Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases| (NASDAQ: KYMR) | Delayed: 86.21 +3.25 (3.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $82.96 | 52 Week High | $ | |||
| Open | $82.53 | 52 Week Low | $ | |||
| Day High | $88.58 | P/E | N/A | |||
| Day Low | $82.53 | EPS | $ | |||
| Volume | 625,217 | |||||
